#United States #Boehringer Ingelheim #Ridgefield, Connecticut #Click Therapeutics #CT-155

Pioneering Advances in Schizophrenia Treatment: CT-155 Unveiled

In a remarkable step forward for mental health treatment, Boehringer Ingelheim and Click Therapeutics recently presented pivotal data regarding CT-155, an investigational prescription digital therapeutic (PDT) designed to mitigate the negative symptoms of schizophrenia. During the 38th Annual European College of Neuropsychopharmacology (ECNP) Congress held in Amsterdam, the study’s findings revealed statistically significant reductions in experiential negative symptoms when CT-155 was used alongside traditional antipsychotic therapies.

Key Findings of the Study

The Phase III CONVOKE study, identified by the clinical trial number NCT05838625, evaluated the efficacy and safety of CT-155 in conjunction with standard antipsychotic medications. Notably, it was the first trial to demonstrate a statistically significant alleviation of negative symptoms as measured by the Clinical Assessment Interview for Negative Symptoms, Motivation, and Pleasure Scale (CAINS-MAP).

CT-155 achieved a Cohen's D effect size of -0.36, indicative of a significant 6.8-point reduction in symptom severity over 16 weeks, compared to a 4.2-point improvement observed in the digital control group. This represents a substantial 62% relative improvement in symptom management, emphasizing the therapeutic’s potential in effectively addressing the unmet challenges faced by schizophrenia patients.

Participant Engagement and Retention

The study also highlighted strong participant engagement, with 70.4% of individuals using the CT-155 app until week 15, compared to 76.5% utilizing the digital control app. Remarkably, participants engaged with CT-155 activities on a median of 76 out of 112 possible study days, illustrating the therapeutic's ability to foster consistent patient involvement.

Broad Implications for Schizophrenia Management

Dr. Gregory W. Mattingly, a key investigator in the study, emphasized the significance of these findings in enhancing our understanding of negative symptoms in schizophrenia. He remarked, “The positive primary endpoint results observed from the CT-155 Phase III trial represent an important step forward in exploring how negative symptoms may be better understood, which is an area of long-standing unmet need in mental health care.” This sentiment underscores the vital role that prescription digital therapeutics could play in delivering accessible and consistent psychosocial interventions, especially for patients struggling with motivation and social interaction.

CT-155 incorporates tailored goal-setting techniques to align with each individual's functioning level, aiming to improve accessibility to therapeutic methods while reducing the stigma associated with traditional mental health treatments.

Safety and Tolerability Profile

Another essential aspect of the study's outcome was the therapeutic's safety profile. CT-155 was well-tolerated among participants, with an adverse event (AE) rate of 8.3%, significantly lower than the 13.4% reported for the digital control arm. Importantly, there were no discontinuations linked to CT-155, positioning it as a safe adjunct to existing schizophrenia therapies.

The Need for Effective Solutions

In the United States alone, approximately 3.7 million adults live with schizophrenia, with 60% experiencing negative symptoms. The lack of specific therapies targeting these symptoms highlights an urgent need for innovative solutions such as CT-155. Austin Speier, Chief Strategy Officer at Click Therapeutics, noted the importance of a patient-centered approach in developing CT-155, which engaged over 150 individuals living with schizophrenia to tailor the therapeutic's focus and content effectively.

Future Prospects for CT-155

Looking ahead, the future of CT-155 appears promising as it has already received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). Boehringer Ingelheim is also conducting the Enspirus study to further analyze CT-155's effectiveness in real-world settings, paving the way for deeper insights into its application as a treatment option.

As we stand on the brink of a new era in the management of schizophrenia, CT-155 could represent a significant breakthrough, offering hope for the millions affected by this challenging condition. Both Boehringer Ingelheim and Click Therapeutics remain committed to enhancing treatment methodologies, striving to create accessible solutions that effectively address the persistent challenges faced by those living with schizophrenia and negative symptoms.